Skip to content
value.today
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

🇺🇸 Salt Lake City, Utah, USAPharmaceuticalsFounded 2013
Total raised
$443 M
5 rounds on record
Latest round
$246 M
Sep 2020
First round on record
Sep 2016
Today
Went public
See the company page

Recursion Pharmaceuticals, Inc. is listed today as Recursion Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Recursion Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2020$246 MNo. 5$50 to $250 million

Recursion Pharmaceuticals, Inc.: Raise no. 5, Sep 2020

Investors in this round

49 investors had bought by the notice of Nov 12, 2020: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Recursion Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$246 M of $246 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher C. Gibson · Executive Officer, Director, Promoter
  • Michael Martin Secora · Executive Officer, Promoter
  • Blake C. Borgeson · Director
  • Dean C. Li · Director
  • R. Martin Chavez · Director
  • Robert C. Hershberg · Director
  • Terry-Ann C. Burrell · Director
  • Zachary C. Bogue · Director
  • Zavain C. Dar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher C. Gibson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 12, 2020. Read the notice at the SEC.

equitySEC
Feb 2019$122 MNo. 4$50 to $250 million

Recursion Pharmaceuticals, Inc.: Raise no. 4, Feb 2019

Investors in this round

33 investors had bought by the notice of Aug 13, 2019: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Recursion Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$122 M of $122 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,131,407
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher C. Gibson · Executive Officer, Director, Promoter
  • Blake C. Borgeson · Director
  • Dean C. Li · Director
  • Zachary C. Bogue · Director
  • Zavain C. Dar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • ALLEN & COMPANY (CRD 1042) · New York, New YorkSold in AK, CA, CO, CT, DC, FL, KY, MA, MD, NJ, NY, PA, UT, VA

Signed by Christopher C. Gibson, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 13, 2019. Read the notice at the SEC.

equitySEC
Sep 2017$56 MNo. 3$50 to $250 million

Recursion Pharmaceuticals, Inc.: Raise no. 3, Sep 2017

Investors in this round

26 investors had bought by the notice of Oct 6, 2017: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Recursion Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $60 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Blake C. Borgeson · Executive Officer, Director, Promoter
  • Christopher C. Gibson · Executive Officer, Director, Promoter
  • John Perry Pereira · Executive Officer
  • H. Perry Fell · Director
  • Zachary Perry Bogue · Director
  • Zavain Perry Dar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher C. Gibson, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2017. Read the notice at the SEC.

equitySEC
Sep 2016$15 MNo. 2$10 to $50 million

Recursion Pharmaceuticals, Inc.: Raise no. 2, Sep 2016

Investors in this round

18 investors had bought by the notice of Dec 2, 2016: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Recursion Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Blake C. Borgeson · Executive Officer, Director, Promoter
  • Christopher C. Gibson · Executive Officer, Director, Promoter
  • Dean Y. Li · Executive Officer, Promoter
  • H. Perry Fell · Director
  • Reid Perry Hutchins · Director
  • Zavain Perry Dar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher C. Gibson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 2, 2016. Read the notice at the SEC.

equitySEC
Sep 2016$4 MNo. 1$2 to $10 million

Recursion Pharmaceuticals, Inc.: Raise no. 1, Sep 2016

Investors in this round

31 investors had bought by the notice of Sep 14, 2016: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Recursion Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Blake C. Borgeson · Executive Officer, Director, Promoter
  • Christopher C. Gibson · Executive Officer, Director, Promoter
  • Dean C. Li · Executive Officer, Director, Promoter · Dr. Li ceased to be a director upon conversion of the LLC to a corporation.
  • H. Perry Fell · Director
  • Reid Perry Hutchins · Director · Mr. Hutchins became a director on September 2, 2016
  • Zavain Perry Dar · Director · Mr. Dar became a director on September 2, 2016.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Reflects the issuance of LLC preferred units.”

Signed by Christopher C. Gibson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 14, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Recursion Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Operating revenue $74.26 million (99%), Grant revenue $420,000 (1%).

    Annual report (SEC XBRL) · Dec 2025

  • Recursion Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2020

Products and services#

No products or services of Recursion Pharmaceuticals, Inc. are on record.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in Recursion Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Blake BorgesonPersonnot statednot statedHeld Series A and A-1 preferred stock, director (Form 3, 2021)SEC Form 3
Christopher GibsonPersonnot statednot statedHeld Series A and A-1 preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Data Collective IV GP, LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Data Collective IV, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
DCVC Opportunity Fund II GP, LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
DCVC Opportunity Fund II, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Dcvc V GP, LLCOthernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Dcvc V, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Lux Co-Invest Opportunities, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Lux Co-Invest Partners, LLCFund or asset managernot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Lux Venture Partners IV, LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Lux Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Mamoura Diversified Global Holding PJSCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Michael SecoraPersonnot statednot statedHeld Series D preferred stock (Form 3, 2021)SEC Form 3
Mubadala Investment Co PJSCFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 49 investors.

Largest shareholders today

Institutions holding Recursion Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Recursion Pharmaceuticals, Inc.
NameRoleNamed in
Christopher C. GibsonExecutive officerNov 2020
Michael Martin SecoraExecutive officerNov 2020
Blake C. BorgesonExecutive officerOct 2017
John Perry PereiraExecutive officerOct 2017
Dean Y. LiExecutive officerDec 2016
Dean C. LiDr. Li ceased to be a director upon conversion of the LLC to a corporation.Sep 2016
Blake C. BorgesonDirectorNov 2020
Christopher C. GibsonDirectorNov 2020
Dean C. LiDirectorNov 2020
R. Martin ChavezDirectorNov 2020
Robert C. HershbergDirectorNov 2020
Terry-Ann C. BurrellDirectorNov 2020
Zachary C. BogueDirectorNov 2020
Zavain C. DarDirectorNov 2020
H. Perry FellDirectorOct 2017
Zachary Perry BogueDirectorOct 2017
Zavain Perry DarDirectorOct 2017
Reid Perry HutchinsDirectorDec 2016
Dean Y. LiDr. Li ceased to be a director upon conversion of the LLC to a corporation.Sep 2016
Christopher C. GibsonPromoterNov 2020
Michael Martin SecoraPromoterNov 2020
Blake C. BorgesonPromoterOct 2017
Dean Y. LiPromoterDec 2016
Dean C. LiDr. Li ceased to be a director upon conversion of the LLC to a corporation.Sep 2016

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.